Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Treatment failure rates
Systematic review	928 people	Treatment failure rates 2 weeks 262/476 (55%) with allylamines 355/452 (79%) with placebo	RR 0.69 95% CI 0.56 to 0.87	Small effect size	allylamines
Systematic review	1116 people	Treatment failure rates 6 weeks 144/566 (25%) with allylamines 443/550 (81%) with placebo	RR 0.33 95% CI 0.24 to 0.44	Moderate effect size	allylamines
Systematic review	612 people	Treatment failure rates 2 weeks 191/314 (61%) with naftifine 243/298 (82%) with placebo	RR 0.75 95% CI 0.60 to 0.93	Small effect size	naftifine
Systematic review	607 people	Treatment failure rates 6 weeks 94/309 (30%) with naftifine 245/298 (82%) with placebo	RR 0.42 95% CI 0.30 to 0.59	Moderate effect size	naftifine
Systematic review	316 people	Treatment failure rates 2 weeks 71/162 (44%) with terbinafine 112/154 (73%) with placebo	RR 0.58 95% CI 0.31 to 1.08		Not significant
Systematic review	40 people	Treatment failure rates 6 weeks 2/18 (11%) with terbinafine 21/22 (95%) with placebo	RR 0.17 95% CI 0.05 to 0.57	Large effect size	terbinafine
RCT	324 people with interdigital tinea pedis	Treatment failure rates 120/190 (63%) with terbinafine 14/83 (17%) with placebo	P <0.0001	Effect size not calculated	terbinafine
Mycological cure rates
RCT 3-armed trial	84 people	Mycological cure rates 5/29 (17%) with terbinafine 1% 4/28 (14%) with terbinafine 3% 3/27 (12%) with placebo	Significance assessment between groups not reported
RCT	84 people	Mycological cure rates 4 weeks 18/29 (69%) with terbinafine 1% 4/27 (16%) with placebo	P <0.0001	Effect size not calculated	terbinafine
RCT	84 people	Mycological cure rates 4 weeks 18/28 (72%) with terbinafine 3% 4/27 (16%) with placebo	P <0.0001	Effect size not calculated	terbinafine
RCT	84 people	Mycological cure rates 6 weeks 25/29 (86%) with terbinafine 1% 3/27 (11%) with placebo	P <0.0001	Effect size not calculated	terbinafine
RCT	84 people	Mycological cure rates 6 weeks 9/28 (68%) with terbinafine 3% 3/27 (11%) with placebo	P <0.0001	Effect size not calculated	terbinafine